Senior Dir, Corporate Affairs & Oncology Policy — Spain

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS?added cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC?), a RAS(ON) multi?selective inhibitor; elironrasib (RMC?),a RAS(ON) G12C?selective inhibitor; zoldonrasib (RMC?),a RAS(ON) G12D?selective inhibitor; and RMC?, a RAS(ON)G12V?selective inhibit…